How PancraGEN Works

PancraGEN is a cutting edge, proprietary integrated molecular pathology test that assesses the cumulative DNA mutations in key oncogenes and tumor suppressor genes associated with pancreatic cancer. PancraGEN can help assess risk of malignancy in patients with cysts and enhance your diagnostic tools such as EUS imaging, CEA, Cytology and other risk factors by providing more information for use in management decisions.

PancraGEN Identifies:

  • Quality and Quantity of DNA in cyst fluid
    High levels of intact DNA are associated with actively dividing cells
  • Oncogene Mutations
    KRAS and GNAS
  • Tumor Suppressor Gene Mutations
    Tumor Suppressor GenesGenomic Loci
    VHL, OGG13p
    PTEN, MXI110q
    TP5317p
    SMAD4, DCC18q
    CDKN2A9p
    RNF43, NME117q
    PSEN2, TFF121q
    CMM1, LMYC1p
    MCC, APC5q
    NF222q

Specimen Types:

  • Aspirated pancreatic cyst fluid

The Report

The PancraGEN Results Report provides an assessment for risk of cancer to help you with long-term patient management strategies.

Download Sample Report

The PancraGEN report includes:

Biological Behavior

Categorizes patients into four groups according to their risk of cancer:

Low Risk Supports Surveillance
BenignStatistically Indolent (SI)
97% probability of benign outcome at follow-up for up to nearly 8 years97% probability of benign outcome at follow-up for up to nearly 8 years
High Risk Supports Intervention
Statistically Higher Risk (SHR)Aggressive
31x increased risk of cancer (HR=31, P<0.0001)76x increased risk of cancer (HR=76, P<0.0001)

Molecular Results

  • DNA Quantity and Quality
  • Oncogene Point Mutations (KRAS and GNAS)
  • Tumor Suppressor Gene Mutations

Nonmolecular Results

AccuCEA & Amylase results if generated and run by Interpace Diagnostics
(Any test information provided to Interpace Diagnostics by the submitting physician will not be included here, but incorporated into the Patient Profile section and referenced in the Comment section)

Diagnostic Category & Integrated Diagnostic Features

Provides a detailed description of the patient’s diagnostic category and risk of cancer including the specific features and information considered in determining the patient’s integrated diagnosis.

Patient Profile

Summarizes clinical and molecular features used to determine diagnostic category predicting current and future biological behavior.

  1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
  2. V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
  3. BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
  4. Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
  5. Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
  6. Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017